RE:Spectral TradingDomino55 wrote: We are down to less than $10,000 worth per day on both exchanges, at historic lows.
it is shocking how little interest there is in the company. Where is the promised shareholder value.
Hey Dom
Creating shareholder value, would require that the Company make reasonable attempts to generate more interest in the stock. It means
supporting the demand side of the equation - and it would require, at the very least, some sort of reasonable marketing/promotional effort. That has been sorely lacking for years, IMO.
Low cost
alternatives to rectify the situation (and as you say, build shareholder awareness & value, in the meantime, and as the Trials progress) might include:
- A proactive, more shareholder friendly IR department
- More Analyst Coverage (one has to believe that products that could potentially save hundreds of thousands of US lives, and reduce ICU costs by billions of dollars, would - if properly laid out to the investment , might spike the interest of many an Analyst and then investors). For that matter, what are our existing partners doing (e.g Paradigm, Walden and AGP) to bring in new retail and institutional investors? They have all benefited in terms of commissions, fees, shares and sweetnemers. What have we got in return, in terms of measurable publicity and assitance in generating more demand?
- Perhaps some more discussion from Management about the multiple and possible (likely?) Covid solutions that we have? For some reason, we seem to want to avoid talking about it - except in medical video discussions amoungst KOL's. What about PMX's ability to aid in saving lives (e.g. to treat severe Covid patients that become endotoxemic while in ICU's), Dialco's entry into Home Dialysis (made more urgent due to Covid), Triaging patients with EAA's, etc.? Other public companies would jump at the chance to promote such possibilities. Many already make claims of possible solutions, with FAR LESS in their tool kits and or that are many years/decades behind in terms of FDA approval (several, in fact, within the hemoperfusion field itself). This supports their share prices and lowers their cost of capital.
- An upgraded US listing (at minimal cost in relation to the cost of issuing far too many shares when cash is needed, especially in a saturated Cdn market - and especially while there seems to be very limited, to no, marketing effort )
- regular and updated Investor Presentations made available, and up-to-date, at all times
It's almost as if they prefer it this way (being way off the radar) for some reason ? If true, this in itself suggests that the interests of all shareholders are NOT currently aligned, despite their claims to the contrary. Not every investor has the same timelines, nor the same access to underlying facts, developments, ongoing negotiations with majors, and partnership parameters. As a consequence, they rely & count on the management of public companies that they own, to ABP (always be promotional).
MM